Geron (GERN) Amortization of Deferred Charges (2021 - 2026)
Geron (GERN) posted Amortization of Deferred Charges of $286000.0 for Q1 2026, up 1.06% sequentially from $283000.0 in Q4 2025, and up 13.04% YoY from $253000.0 in Q1 2025.
Geron (GERN) Amortization of Deferred Charges (2021 - 2026) Analysis & Trends
Geron has reported Amortization of Deferred Charges for 6 years, with the latest figure at $286000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 13.04% year-over-year to $286000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (up 130.19% YoY) and the FY2025 annual result came in at $1.1 million, up 134.46% from the prior year.
- Amortization of Deferred Charges improved to $286000.0 in Q1 2026 per GERN's latest filing, from $283000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $818000.0 in Q3 2022 and troughed at -$3.6 million in Q4 2024.
- A 5-year average of -$34117.6 and a median of $242000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 978.12% in 2024, down 2290.07% in 2024.
- Over 5 years, Amortization of Deferred Charges stood at -$523000.0 in 2022, then jumped by 71.13% to -$151000.0 in 2023, then tumbled by 2290.07% to -$3.6 million in 2024, then surged by 107.84% to $283000.0 in 2025, then climbed by 1.06% to $286000.0 in 2026.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $286000.0, $283000.0, and $430000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 298,000.00 |
| Jun 30, 2026 | 298,000.00 |
| Mar 31, 2026 | 286,000.00 |
| Mar 31, 2026 | 286,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Dec 31, 2025 | 283,000.00 |
| Sep 30, 2025 | 430,000.00 |
| Sep 30, 2025 | 430,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Jun 30, 2025 | 105,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | -3.61 Mn |
| Dec 31, 2024 | -3.61 Mn |
| Sep 30, 2024 | -991,000.00 |
| Sep 30, 2024 | -991,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Jun 30, 2024 | 690,000.00 |
| Mar 31, 2024 | 802,000.00 |
| Mar 31, 2024 | 802,000.00 |